Jaba Recordati, a pharmaceutical company with over 80 years of history, is the Portuguese branch of the multinational group Recordati present worldwide, a specialty pharmaceutical group dedicated to partnering, discovering and developing innovative, value-added medicines that improve quality of life and help people to enjoy longer, healthier and more productive lives. We are present in 4 segments of the pharma business: branded products, generic, OTCs and orphan drugs. Also we started in the last years a internationalization process for the PALOPs countries in Africa, allowing this patients and health technicians to be treated with the same innovative medicines existing in Europe. We are the 18th company of Portuguese IMS ranking and the distinguishing factors of our company are : product and organizational innovation , coupled with a strong ethical and scientific rigor , as well as economic and financial.
Jaba Recordati S.A.
Lagoas Park, Edifício 5, Torre C, Piso 3
2740-298 Porto Salvo, Portugal
Tel: +351 21 432 95 00
Fax: +351 21 915 19 30
website : www.jaba.pt
Nelson Pires, General Manager of Jaba Recordati, the Portuguese affiliate of the Recordati Group, outlines the affiliate’s expansion into the PALOPS markets and demonstrates how the company has grown during…
Pedro Moura is the first Portuguese managing director of Merck in Portugal, taking on the role in September 2017 after a stint in HQ in Darmstadt, Germany. Moura discusses Merck’s…
Enrique Santos, president of the Spanish Chamber of Commerce in Portugal since 1998, observes the rapid change in the volume and nature of investments into Portugal in recent years. Santos…
Azevedos is one of the oldest pharmaceutical brands in Portugal. Lead by Thebar Miranda, president for 30 years it operates across Portuguese speaking companies and distributes worldwide. In this interview,…
Florian Ibe, managing director at Bayer Portugal, discusses market access hurdles, as well as Portugal’s expertise in scientific and clinical research and highly educated workforce. In three years of his…
Paulo Lilaia, president of the board of APOGEN and CEO of Generis, highlights the need for generics in the healthcare system and the government’s approach to their implementation. He also…
The Portuguese secretary of state for industry invites readers to discover the vibrant tech landscape in Portugal. Ana Teresa Lehmann unravels the reasons why Portugal is such an exciting investment…
Filipa Costa returned to Portugal in September 2016 to take on the leadership of the fastest growing multinational affiliate in the country – Janssen. In this interview, she reveals her…
Heitor Costa, Executive Director for APIFARMA, the Portuguese Pharmaceutical Industry Association, outlines the recent improvements in industry and governmental agreements, the importance of non-prescription medicines, and raising societal awareness on…
A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other developed European markets, with a jump in the number of approvals for 2017.…
Graca Didier, secretary general of AmCham Portugal, discuss the role of her chamber of commerce in promoting strong relations between America and Portugal. In addition, she comments on the cultural…
Joaquim Cunha, executive director of Health Cluster Portugal – a private, non-profit organisation dedicated to the consolidation of Portugal’s healthcare industry – discusses the up and coming changes to the…
Oscar Gaspar, VP of the Confederation of Portuguese Industry (CIP), president of the Portuguese Association of Private Hospitalization and former secretary of state for health (2009-2011), provides an informative insight…
See our Cookie Privacy Policy Here
